These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3120200)

  • 1. The Japanese experience: use of transrectal ultrasound in the evaluation of tumor response to various treatment modalities.
    Watanabe H
    Prog Clin Biol Res; 1987; 237():195-208. PubMed ID: 3120200
    [No Abstract]   [Full Text] [Related]  

  • 2. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 6. LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
    Jacobi GH
    Recent Results Cancer Res; 1990; 118():174-85. PubMed ID: 2146724
    [No Abstract]   [Full Text] [Related]  

  • 7. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance with hormonal treatment for prostate cancer.
    Kaisary AV
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):359-66. PubMed ID: 8696636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy.
    De Sy WA; De Wilde P; De Meyer JM; Casselman J; Desmet R; Renders G; Schelfhout W
    Acta Urol Belg; 1988; 56(4):581-8. PubMed ID: 2974680
    [No Abstract]   [Full Text] [Related]  

  • 11. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 13. [Orchiectomy should be chosen instead of LHRH analogs in the treatment of prostatic cancer].
    Liedberg CF
    Lakartidningen; 1989 Jan; 86(3):120. PubMed ID: 2643014
    [No Abstract]   [Full Text] [Related]  

  • 14. The U.S.A. experience: diagnosis and follow-up of prostate malignancy by transrectal ultrasound.
    Huben RP
    Prog Clin Biol Res; 1987; 237():153-9. PubMed ID: 3317427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid drop in serum testosterone after bilateral subcapsular orchiectomy.
    Arcadi JA
    J Surg Oncol; 1992 Jan; 49(1):35-8. PubMed ID: 1548879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 18. Transrectal ultrasound in the diagnosis, staging, guided needle biopsy, and screening for prostate cancer.
    Lee F
    Prog Clin Biol Res; 1987; 237():73-109. PubMed ID: 3317434
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of ultrasonography of the prostate.
    Muldoon L; Resnick MI
    Urol Clin North Am; 1989 Nov; 16(4):693-702. PubMed ID: 2683299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.